Skip to main content

Advertisement

Figure 3 | Journal of Hematology & Oncology

Figure 3

From: Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts

Figure 3

Mean change from baseline to week 24 in quality of life, functional domains, and symptoms assessed by the EORTC QLQ-C30. Note: n = 32 for all scales except the Role Functioning and Cognitive Functioning domain, in which n = 31. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30; QoL, quality of life; SEM, standard error of the mean.

Back to article page